FATE Strangle Strategy
FATE (Fate Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
FATE (Fate Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $248.2M, a beta of 2.14 versus the broader market, a 52-week range of 0.91-2.47, average daily share volume of 2.0M, a public-listing history dating back to 2013, approximately 181 full-time employees. These structural characteristics shape how FATE stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 2.14 indicates FATE has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a strangle on FATE?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current FATE snapshot
As of May 15, 2026, spot at $1.75, ATM IV 147.10%, IV rank 27.11%, expected move 42.17%. The strangle on FATE below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on FATE specifically: FATE IV at 147.10% is on the cheap side of its 1-year range, which favors premium-buying structures like a FATE strangle, with a market-implied 1-standard-deviation move of approximately 42.17% (roughly $0.74 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated FATE expiries trade a higher absolute premium for lower per-day decay. Position sizing on FATE should anchor to the underlying notional of $1.75 per share and to the trader's directional view on FATE stock.
FATE strangle setup
The FATE strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With FATE near $1.75, the first option leg uses a $1.84 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed FATE chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 FATE shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $1.84 | N/A |
| Buy 1 | Put | $1.66 | N/A |
FATE strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
FATE strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on FATE. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on FATE
Strangles on FATE are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the FATE chain.
FATE thesis for this strangle
The market-implied 1-standard-deviation range for FATE extends from approximately $1.01 on the downside to $2.49 on the upside. A FATE long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current FATE IV rank near 27.11% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on FATE at 147.10%. As a Healthcare name, FATE options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to FATE-specific events.
FATE strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. FATE positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move FATE alongside the broader basket even when FATE-specific fundamentals are unchanged. Always rebuild the position from current FATE chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on FATE?
- A strangle on FATE is the strangle strategy applied to FATE (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With FATE stock trading near $1.75, the strikes shown on this page are snapped to the nearest listed FATE chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are FATE strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the FATE strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 147.10%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a FATE strangle?
- The breakeven for the FATE strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current FATE market-implied 1-standard-deviation expected move is approximately 42.17%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on FATE?
- Strangles on FATE are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the FATE chain.
- How does current FATE implied volatility affect this strangle?
- FATE ATM IV is at 147.10% with IV rank near 27.11%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.